Jump to content

NEFA (drug)

From Wikipedia, the free encyclopedia
NEFA
Identifiers
  • (4aR,9aS)-N-Ethyl-4,4a,9,9a-tetrahydro-1H-fluoren-4a-amine
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H19N
Molar mass213.324 g·mol−1
3D model (JSmol)
  • CCN[C@]12CC=CC[C@H]1CC3=CC=CC=C23
  • InChI=1S/C15H19N/c1-2-16-15-10-6-5-8-13(15)11-12-7-3-4-9-14(12)15/h3-7,9,13,16H,2,8,10-11H2,1H3/t13-,15 /m0/s1
  • Key:DRCWOKJLSQUJPZ-DZGCQCFKSA-N
  (verify)

NEFA is a moderate affinity NMDA antagonist (IC50 = 0.51 μM). It is a structural analog of phencyclidine.[1] It was first synthesized by a team at Parke-Davis in the late 1950s.[2]

References

[edit]
  1. ^ Dilmore JG, Johnson JW (1998). "Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine". Biophysical Journal. 75 (4): 1801–16. Bibcode:1998BpJ....75.1801D. doi:10.1016/S0006-3495(98)77622-2. PMC 1299852. PMID 9746522.
  2. ^ GB Patent 893920 - Polycyclic amino compounds and methods for their production


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=NEFA_(drug)&oldid=1217601459"